The recent ACB-CMED-HIP scenario in many ways should not have come as a surprise; that is to say, the individual companies may have been a surprise to some but not the idea of a hostile takeover along with what may be considered a poison pill in response.
Our pioneering strategies in 2017 paved the way and it is little doubt others repackaged and named them as their own afterwards. Strategies such as the “late stage applicants”; “low shares outstanding and market cap combined with revenues”; “new kids on the block”; “California Dreaming”; “Vegas”; New World Meets the Old World” (Hemp/Marijuana companies and modern applications such as cryptocurrency); “Germany”, “Animal Care Sector”; and so forth. We predicted in advance that ACB would take a position in a Hemp company and that Health Canada would expedite the application and approval process. The ROI from these strategies are not only in the triple digits but the average is just under double the ROI of the Marijuana Index itself with one company’s ROI at 1200%. All of these strategies remain in effect but can always benefit from fine tuning and providing you, our readers, more tools for your toolbox.
161